Are the indications for administering ticagrelor and clopidogrel in patients with acute coronary syndrome different? Is the medical, insurance, or socioeconomic profile a consideration when choosing one over the other?

Both ticagrelor and clopidogrel are indicated for ACS but ticagrelor is preferred for initial treatment due to superior cardiovascular outcomes. Considerations such as genetic profiles, contraindications, and bleeding risks play significant roles in the clinical decision between these agents.